Document is current
Any future updates will be listed below
-
Authors
Yamamoto, Yoshiyuki
Yukami, Hiroki
Yamaguchi, Tatsuro
Ohori, Hisatsugu
Nagasu, Sachiko
Kagawa, Yoshinori
Sugimoto, Naotoshi
Sonoda, Hiromichi
Yamazaki, Kentaro
Takashima, Atsuo
Okuyama, Hiroyuki
Hasegawa, Hiroko
Kondo, Chihiro
Baba, Eishi
Matsumoto, Toshihiko
Kawamoto, Yasuyuki
Kataoka, Masato
Shindo, Yoshiaki
Ishikawa, Toshiaki
Esaki, Taito
Kito, Yosuke
Sato, Takeo
Funakoshi, Taro
Yamaguchi, Toshifumi
Shimada, Yasuhiro
Moriwaki, Toshikazu https://orcid.org/0000-0001-7702-122X
-
Funding
Funding for this research was provided by:
the Japanese Society for Cancer of the Colon and Rectum
- License Information
-
More Information
Article History
Received: 2 June 2024
Accepted: 22 August 2024
First Online: 28 August 2024
Declarations
:
: Yoshinori Kagawa has received honoraria from Chugaim Ono, Merck Serono, Takeda, Eli Lilly, MSD, and Taiho. Naotoshi Sugimoto has received honoraria from Chugai, Cai-ichi Sankyo, Eli Lilly Japan, MSD, and Ono, reserch funding from Astellas, Ono, MSD, Pfizer, Chugai, Eizai and Seagen. Kentaro Yamazaki has received honoraria from Chugai, Takeda, Taiho, Eli Lilly, Merck Serono, MSD, and Ono, research funding from Taiho. Atsuo Takashima has received honoraria from Eli Lilly, Ono, Taiho, Chugai, Takeda, and Merck Serono, research funding from MSD, AstraZeneca, Amgen, Eisai, BMS, and Ono. Eishi Baba has received honoraria from Chugai, scholarship donation from Chugai and Taiho. Toshihiko Matsumoto has received honoraria from Chugai, research funding from Sanofi and Astellas. Taito Esaki has received research funding from MSD, Ono, Chugai, Amgen, ALX Oncology, Seagen, Taiho, Daiichi Sankyo, Pfyzer, Jazz Pharmaceuticals, Asahikasei Phama, Quintiles, Astellas Amgen Biopharm, Novartis, and Syneos Health Clinica. The other authors declare that they have no competing interests.
